Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Cardiff Oncology, Inc. (TROV)
|
Add to portfolio |
|
|
Price: |
$8.56
| | Metrics |
OS: |
44.7
|
M
| |
|
|
Market cap: |
$382
|
M
| |
|
|
Net cash:
|
$118
|
M
| |
$2.65
|
per share
|
EV:
|
$264
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 0.4 | 0.4 | 0.4 | 0.2 | 0.4 | 0.5 | 0.4 | 0.3 |
Revenue growth | 7.5% | -1.9% | 49.6% | -35.3% | -25.1% | 32.6% | 21.8% | 11.6% |
Cost of goods sold | 0.0 | 0.0 | 0.0 | -16.9 | 0.6 | 1.8 | 1.7 | 0.6 |
Gross profit | 0.4 | 0.4 | 0.4 | 17.2 | -0.2 | -1.3 | -1.3 | -0.3 |
Gross margin | 100.0% | 100.0% | 100.0% | 7018.6% | -57.9% | -258.4% | -354.1% | -101.1% |
Selling, general and administrative | 13.2 | 11.8 | 8.2 | 5.8 | 8.0 | 14.2 | | |
Sales and marketing | | | | | | | 11.5 | 6.4 |
Research and development | 27.1 | 17.4 | 11.2 | 11.2 | 8.2 | 7.9 | 15.0 | 10.6 |
General and administrative | | | | | | | 11.5 | 7.9 |
EBIT | -39.9 | -28.9 | -19.1 | -16.7 | -16.4 | -23.4 | -39.4 | -25.3 |
EBIT margin | -10337.3% | -8037.6% | -5214.8% | -6817.8% | -4331.9% | -4634.2% | -10327.5% | -8079.5% |
Pre-tax income | -38.7 | -28.3 | -19.3 | -16.4 | -16.5 | -24.9 | -39.2 | -27.5 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | -38.7 | -28.3 | -22.6 | -16.7 | -19.3 | -24.9 | -39.2 | -27.5 |
Net margin | -10033.2% | -7887.2% | -6174.3% | -6829.3% | -5089.5% | -4932.9% | -10294.1% | -8789.7% |
|
Diluted EPS | ($0.89) | ($0.73) | ($1.08) | ($2.80) | ($8.26) | ($51.76) | ($1.30) | ($1.04) |
Shares outstanding (diluted) | 43.6 | 39.0 | 20.9 | 6.0 | 2.3 | 0.5 | 30.3 | 26.5 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|